搜尋結果
2024年5月15日 · Informationen zum Medikament Comirnaty Original/Omicron BA.4-5 (15/15 Mikrogramm)/Dosis Injektionsdispersion BUND APO von Bundesinstitut Für Impfstoffe Und Biomedizinische Arzneimittel Zentrum Für Pandemie-Impfstoffe Und Therapeutika mit Wirkstoff SARS-CoV-2-Spike-Glycoprotein (BNT162b2), SARS-CoV-2-Spike-Glycoprotein (BNT), (Omicron BA.4/BA.5) (ATC J07BN01 - Covid-19, RNA-basierter Impfstoff)
5 天前 · Nel maggio scorso Santé Publique France ha pubblicato un report che mette a confronto i sintomi osservati nei casi di Omicron BA.1 in Francia con i nuovi casi di BA.4 e BA.5. Molte le somiglianze, ma sono stati segnalati maggiormente problemi di affaticamento, tosse, febbre e mal di gola, mentre la durata dei sintomi stessi è in media di quattro giorni .
2024年5月14日 · Results indicate the activation and expansion of Omicron-specific naïve B cells generated by first-time Omicron exposure helped to alleviate CoronaVac-induced immune imprinting, and the absence of this process should have caused the persistent immune imprinting seen in mRNA vaccine recipients. SARS-CoV-2 ancestral strain-induced immune imprinting poses great challenges to vaccine updates ...
1 天前 · hVIVO plc has announced a £2.5 million contract to establish the world’s first Omicron BA.5 challenge model using its new CL3 quarantine facilities in Canary Wharf. The study, which will ...
2024年5月15日 · Fachinformation Comirnaty Original/Omicron BA.1 (15/15 Mikrogramm)/Dosis Injektionsdispersion BUND APO von Bundesinstitut Für Impfstoffe Und Biomedizinische Arzneimittel Zentrum Für Pandemie-Impfstoffe Und Therapeutika mit Wirkstoff SARS-CoV-2-Spike
2024年5月26日 · CoronaVac and BBIBP‐CorV vaccines against SARS‐CoV‐2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study 奥密克戎BA.5.2和BF.7流行期间抗新型冠状病毒冠状病毒和BBIBP-CorV疫苗的回顾性队列研究
